New River Pharmaceuticals, Inc. and USFDA Conducted End-of-Phase II Meeting on NRP290 (Product Candidate for Acute Pain)
Company officials of New River Pharmaceuticals Inc. (Nasdaq: NRPH) have met last week on an end-of-phase II meeting with staff members of the Center for Drug Evaluation and Research of the USFDA and discussed NRP290, a hydrocodone derivative under development as a potential treatment for acute pain which has already undergone two pharmacokinetic clinical studies.
According to RJ Kirk, New River's chairman and CEO:
"This is certainly an exciting time for New River. This week's discussions with the FDA will help us finalize our efficacy and safety studies and define our regulatory strategy as we advance NRP290 into late-stage testing."
A specialty pharmaceutical company, New River Pharmaceuticals Inc. develops novel pharmaceuticals that are generational improvements of widely prescribed drugs in large and growing markets.
Comment Preview